Vivek Subbiah: The pre-proof version of the editorial commentary on Optimizing Tomorrow’s Drug Development with Project Optimus
Vivek Subbiah shared his recent article on LinkedIn:
“Pleased to share the pre-proof version of the editorial commentary just published ESMO – European Society for Medical Oncology flagship journal Annals of Oncology.
Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology.”
Tittle: Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology
Author: Vivek Subbiah
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (Vivek Subbiah USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023